What is the LACTIN-V Study?
This is a medical research study sponsored by the National Institutes of Health (NIH) Division Of Microbiology And Infectious Diseases through the Sexually Transmitted Infections Clinical Trials Group (STI-CTG) led by study doctors Craig Cohen, MD, MPH, Anke Hemmerling, MD, PhD, MPH Misa Perron-Burdick, MD, MAS and Sara Newmann, MD, MPH, from the University of California, San Francisco (UCSF) Department of Obstetrics, Gynecology and Reproductive Sciences.
The aim of this study is to test a vaginal powder made of naturally occurring probiotic, Lactobacillus crispatus CTV-05 (LACTIN-V, Osel, Inc.) administered following a 5-day treatment with Metronidazole (MetroGel®) to treat bacterial vaginosis (BV), which could reduce the incidence of BV recurrence when compared to placebo. BV is a condition many women suffer from and it increases the risk of these women of getting infected with various sexually transmitted diseases. Millions of people throughout the world could benefit from such a product.
The LACTIN-V Study enrolled our last study participant in August 2018. We are currently following up with our last study participants and anticipate to start analyzing our findings in Spring of 2019, stay tuned for more information.
Do you have questions?
Contact us at 1-844-LACTINV (1-844-522-8468) or
email us at LACTIN-V@ucsf.edu.
We look forward to hearing from you!